Phase I population pharmacokinetics of irofulven.
Our aim was to develop a population pharmacokinetic model for irofulven and to assess covariates that might affect irofulven pharmacokinetics. Irofulven was administered by 5- or 30-min i.v. infusion to cancer patients during a phase I study. Blood samples were collected over 4 h. Plasma samples were analyzed to quantitate irofulven by high-performance liquid chromatography. Population pharmacokinetic analysis was performed using a non-linear mixed effects modeling program, MP2. Fifty-nine patients were available for pharmacokinetic analysis. Irofulven plasma concentration-time profiles were best described by a two-compartment pharmacokinetic model. Clearance and central volume of distribution were not significantly influenced by individual characteristics, i.e. body weight (BW), body surface area (BSA), age and gender. Final parameter estimates of clearance and central volume of distribution were 616 l/h and 37 l, respectively, resulting in a very short terminal half-life of less than 10 min. A relatively high level of variability was observed in irofulven pharmacokinetics, which was mainly due to a significant residual variability, 39%. For a 30-min irofulven infusion, the optimal sampling schedule for clearance estimation using the Bayesian method was the three time points 0.35-0.45, 0.80 and 1-1.2 h from the beginning of a 30-min infusion. We conclude that after i.v. infusion of irofulven, plasma clearance was high and not dependent upon patient age, gender, BSA or BW.
Urien
S
S
Pharmacology Department, Rene Huguenin Cancer Center, Saint-Cloud, France. s.urien@stcloud-huguenin.org
Alexandre
J
J
Raymond
E
E
Brain
E
E
Smith
S
S
Shah
A
A
Cvitkovic
E
E
Lokiec
F
F
D000328:Adult; D000368:Aged; D000465:Algorithms; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D015982:Bias; D002851:Chromatography, High Pressure Liquid; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011153:Population; D012494:Sampling Studies; D012717:Sesquiterpenes / Q000493:pharmacokinetics*; D013056:Spectrophotometry, Ultraviolet
D000970:Antineoplastic Agents; D012717:Sesquiterpenes; C102714:irofulven